Yun Li, Xiaohuan Xia, Yi Wang, Jialin C. Zheng
6 min
Alzheimer's disease (AD) is traditionally defined by the accumulation of extracellular beta-amyloid plaques and intracellular neurofibrillary tangles. However, clinical failures of therapies targeting these markers have shifted research focus toward the role of neuroinflammation. Microglia, the brain's primary innate immune cells, are central to this process. While they are responsible for clearing pathogenic proteins, their chronic activation in AD leads to the release of pro-inflammatory cytokines, which exacerbate neuronal damage and contribute to the disease's progression.
Recent research suggests that microglial activation is not merely a response to amyloid or tau, but is preceded by mitochondrial dysfunction. Mitochondria are essential for the high energy demands of microglial immune functions. In AD, these organelles suffer from structural alterations, reduced ATP production, and increased reactive oxygen species (ROS). Specifically, mitochondrial DNA (mtDNA) is highly vulnerable to oxidative damage due to its lack of histone protection. When damaged, mtDNA can be released into the cytosol or extracellular space, where it acts as a damage-associated molecular pattern (DAMP). This triggers pathways such as the cGAS-STING and NLRP3 inflammasome, which further amplify the inflammatory cycle.
Microglia exhibit metabolic flexibility, allowing them to switch between oxidative phosphorylation (OXPHOS) and glycolysis depending on their activation state. In the context of AD, there is a documented shift toward glycolysis, often referred to as metabolic reprogramming. This shift is associated with glucose hypometabolism, a hallmark of early-stage AD. The downregulation of genes involved in the TCA cycle and the electron transport chain (ETC) suggests that the inability of microglia to maintain efficient energy production is a critical factor in their transition from a protective state to a pathogenic, pro-inflammatory state.
Understanding the link between microglial mitochondrial health and AD pathology opens new avenues for treatment. Rather than focusing solely on amyloid clearance, future therapeutic strategies may target mitochondrial quality control mechanisms, such as mitophagy, or attempt to restore metabolic homeostasis in microglia. By stabilizing mitochondrial function, it may be possible to dampen the neuroinflammatory cascade before it leads to irreversible neuronal loss.
Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly globally. Emerging evidence has demonstrated microglia-driven neuroinflammation as a key contributor to the onset and progression of AD, however, the mechanisms that mediate neuroinflammation remain largely unknown. Recent studies have suggested mitochondrial dysfunction including mitochondrial DNA (mtDNA) damage, metabolic defects, and quality control (QC) disorders precedes microglial activation and subsequent neuroinflammation. Therefore, an in-depth understanding of the relationship between mitochondrial dysfunction and microglial activation in AD is important to unveil the pathogenesis of AD and develop effective approaches for early AD diagnosis and treatment. In this review, we summarized current progress in the roles of mtDNA, mitochondrial metabolism, mitochondrial QC changes in microglial activation in AD, and provide comprehensive thoughts for targeting microglial mitochondria as potential therapeutic strategies of AD.
Sam: How does the cell actually know its power plant is leaking? Does it have some kind of sensor?
Alex: It does. When damaged DNA escapes from the mitochondria and drifts into the wrong part of the cell, it triggers an alarm system. The paper describes one key sensor—think of it as a smoke detector. When it detects that stray DNA, it sets off a loud alarm, causing the cell to release distress signals into the surrounding tissue.
Sam: And those distress signals damage nearby cells too?
Alex: Exactly. And here's where it becomes self-reinforcing. That damage causes neighboring cells to leak their own DNA, which triggers more alarms, which causes more inflammation. It's a feedback loop that's very difficult to stop once it starts. Think of a fire that keeps spreading because the smoke alarms themselves are starting new fires.
Sam: That's a striking image.
Alex: The paper describes one more layer to this. Under normal conditions, cells use a careful, efficient process to generate energy—one that extracts the maximum amount of fuel from nutrients. But when a cell is under stress, it abandons that careful process and switches to a much faster, much less efficient method. The cell gets a short burst of energy, but it's wasteful and unsustainable—like switching from a fuel-efficient engine to one that just burns through everything as fast as possible.
Sam: And over time, the cell can't keep up?
Alex: That's the idea. The cell becomes less capable of maintaining its own health, let alone doing its job of clearing debris from the brain. And so the cycle continues.
Sam: Before we go further—what are the limitations here? Are we talking about studies in animals and cells in a dish, or has this been observed in people?
Alex: That's an important question, and the paper is candid about it. Much of the mechanistic evidence—the detailed picture of how these pathways work—comes from cell studies and animal models. Translating that to human disease is a significant step, and one that requires further research. The paper frames this as a theoretical framework supported by existing evidence, not a clinical conclusion.
Sam: So this is more about pointing researchers in a new direction than announcing a cure?
Alex: Precisely. The value of this kind of work is that it reframes the question. For decades, much of the research effort in Alzheimer's has focused on clearing amyloid plaques from the brain. Several large clinical trials targeting plaques have had limited success. This paper suggests that the energy systems of the brain's immune cells may be a more productive target—not instead of plaques, but as a deeper mechanism that might explain why the disease progresses the way it does.
Sam: It's a shift from looking at the trash on the floor to asking why the cleaning crew stopped working in the first place.
Alex: That's the core insight. And if the framework holds up under further investigation, it opens the door to a different class of potential treatments—ones aimed at restoring the metabolic health of these immune cells rather than just removing the byproducts of their failure.
Sam: What would that even look like as a treatment?
Alex: The paper points to several possibilities that researchers are beginning to explore—compounds that support mitochondrial function, or that help clear damaged mitochondria more efficiently. But it's worth being clear: these are early-stage ideas. Nothing described here is ready for clinical use. The paper's contribution is the conceptual map, not the destination.
Sam: So we're at the stage of understanding the problem more clearly, not solving it yet.
Alex: That is often where meaningful scientific progress begins. A clearer picture of the mechanism is what allows researchers to design better experiments and, eventually, better interventions. Alzheimer's has resisted simple explanations for a long time. Seeing it as a metabolic disease—at the level of the brain's immune cells—may prove to be a more productive lens.
Sam: It's a sobering reminder that diseases this complex rarely have a single cause or a single fix.
Alex: And that complexity is exactly why reframing the question matters. Thanks for listening to ResearchPod.